Disability Status and Prostate Cancer Screening Among US Men Aged 55 to 69 Years.
Nolazco JI, Iezzoni LI, Chen EC, Park ER, Wang W, Leapman MS, Alkhatib KY, Teoh JYC, Cole AP, Mossanen M, Lay AH, Bartels SJ, Kibel AS, Feldman AS, Chang SL
Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS,
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.
Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F
A conserved hormonal signalling-H2A.Z axis rapidly reorganizes 3D chromatin interactions in adipocyte thermogenesis.
Zhang Y, Zheng R, Tsuji T, Wang CH, Liu XY, Xing YH, Darcy J, Lynes MD, Lundh M, Arianti R, Győry F, Dong R, Emanuelli B, Johnstone SE, Rivera MN, Kristóf E, Kahn CR, Chen K, Tseng YH
A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.
Yi Y, Li Y, Wang R, Yu X, Liu Q, Yum C, Zhang Y, Qiao Y, Szczepanski A, Wu S, Li Q, Fazli L, Shen J, Wang X, Li X, Mu P, Schaeffer EM, Hundley HA, Niu H, Chinnaiyan AM, Wang L, Shi J, Jin J, Dong X, Zhao W, Chen K, Cao Q
Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.
Singh R, Venkadakrishnan VB, Imada E, Yamada Y, Brady NJ, Dunmore KE, Garner R, Booker MA, Hanratty B, Haffner MC, Tolstorukov MY, Marchionni L, Robinson BD, Rickman DS, Beltran H
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics.
Xie F, Gjyrezi A, Fein D, Labaf M, Poluben L, Ersoy-Fazlioglu B, Dennehy CM, Voznesensky O, Gad A, Corey E, Varkaris A, Einstein DJ, Bhatt RS, Giannakakou P, Balk SP
cGAS restricts PARP1-mediated microhomology-mediated end joining by suppressing poly-ADP-ribosylation.
Yang H, Gao B, Wu B, Li W, Zhu X, Phoon L, Luo J, Gui F, Zhao W, Jia L, Lan L
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.
Börcsök J, Gopaul D, Devesa-Serrano D, Mooser C, Jonsson N, Cagiada M, Stormoen DR, Ataya MN, Guercio BJ, Kaimakliotis HZ, Iyer G, Lindorff-Larsen K, Dyrskjøt L, Mouw KW, Szallasi Z, Sørensen CS
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Mizuno K, Ku SY, Venkadakrishnan VB, Bakht MK, Sigouros M, Chan J, Trigos A, Driskill JH, Manohar J, King A, Presser AG, Kim MJ, Tewari AK, Long HW, Quigley D, Choueiri TK, Balk S, Hill S, Mosquera JM, Einstein D, Sandhu S, Taplin ME, Beltran H
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Varkaris A, Wang K, Nouri M, Kozlova N, Schmidt DR, Stavridi A, Arai S, Ambrosio N, Poluben L, Jimenez-Vacas JM, Westaby D, Carmichael J, Xie F, Figueiredo I, Buroni L, Neeb A, Gurel B, Chevalier N, Brown L, Voznesensky O, Chen SY, Russo JW, Yuan X, Juric D, Beltran H, De Bono JS, Vander Heiden MG, Einstein DJ, Muranen T, Corey E, Sharp A, Balk SP
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.
Teng M, Guo J, Xu X, Ci X, Mo Y, Kohen Y, Ni Z, Chen S, Guo WY, Bakht M, Ku S, Sigouros M, Luo W, Macarios CM, Xia Z, Chen M, Ul Haq S, Yang W, Berlin A, van der Kwast T, Ellis L, Zoubeidi A, Zheng G, Ming J, Wang Y, Cui H, Lok BH, Raught B, Beltran H, Qin J, He HH
